Compare Novartis AG (NVS) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Tyson Foods, Inc. — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Tyson Foods, Inc. trades at $57.25 (market cap $20.42B). The key difference: Novartis AG is far larger — about 14.2× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays the higher dividend (3.52%). Which is the better fit depends on your goals.
| NVS | TSN | |
|---|---|---|
Market Cap | $290.25B | $20.42B |
Sector | Health | Consumer Staples |
52-Week High | $168.62 | $68.75 |
52-Week Low | $113.50 | $50.72 |
Enterprise Value | $330.27B | $28.01B |
Dividend Yield | 3.17% | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Tyson Foods (TSN) trades at $57.05, down 1.25% with neutral technical indicators. The company shows stable revenue near $54B but thin margins, with a 0.81% net income margin and elevated P/E of 45.67. Recent earnings beat expectations in Q1 2026, while analyst consensus is mixed with a $68.80 price target. Dividend payments continue at $0.51 quarterly.
TSN offers modest growth potential with analyst upside but faces margin pressure and competitive challenges. The stock's valuation appears stretched relative to earnings, while consistent dividends provide income support. Key risks include commodity cost volatility and execution in the competitive protein market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
